Abstract
Background
The American Joint Commission on Cancer, the European Neuroendocrine Tumor Society, and the North American Neuroendocrine Tumor Society all classify colon neuroendocrine tumor (NET) nodal metastasis as N0 or N1. This binary classification does not allow for further prognostication by the total number of positive lymph nodes. This study aimed to evaluate whether the total number of positive lymph nodes affects the overall survival for patients with colon NET.
Methods
The National Cancer Database was used to identify patients with colon NET. Nearest-neighborhood grouping was performed to classify patients by survival to create a new nodal staging system. The Surveillance, Epidemiology, and End Results database was used to validate the new nodal staging classification.
Results
Colon NETs were identified in 2472 patients. Distinct 5-year survival rates were estimated for the patients with N0 (no positive lymph nodes; 69.8%; 95% confidence interval [CI], 66.7–72.7%), N1a (1 positive lymph node; 63.9%; 95% CI, 59.6–68.0%), N1b (2–9 positive lymph nodes; 38.9%; 95% CI, 35.4–42.3%), and N2 (≥ 10 positive lymph nodes; 15.7%; 95% CI, 11.9–20.0%; p < 0.001) nodal classifications. The validation population showed distinct 5-year survival rates with the new nodal staging. In multivariable Cox regression, the new nodal stage was a significant independent predictor of overall survival.
Conclusions
The number of positive locoregional lymph nodes in colon NETs is an independent prognostic factor. For patients with colon NETs, N0, N1a, N1b, and N2 classifications for nodal metastasis more accurately predict survival than current staging systems.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25,531). Ann Oncol. 2013;24:3040–4.
Amin MA (ed) AJCC cancer staging manual. 8th ed. New York: Springer; 2017.
Chagpar R, Chiang Y, Xing Y, et al. Neuroendocrine tumors of the colon and rectum: prognostic relevance and comparative performance of current staging systems. Ann Surg Oncol. 2013;20:1170–8.
Shen C, Yin Y, Chen H. Neuroendocrine tumors of the colon and rectum: validation of clinical and prognostic values of the World Health Organization 2010 grading classifications and European Neuroendocrine Tumor Society staging systems. Oncotarget. 2017;8:22123–34.
Lin H, Lin J, Lin C, et al. Clinicopathological analysis of colorectal carcinoid tumors and patient outcomes. World J Surg Oncol. 2014;12:366.
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.
Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.
Maggard MA, O’Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004;240:117–22.
Anthony LB, Strosberg JR, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendrocrine tumors (NETS). Pancreas. 2010;39:767–74.
Rindi, G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757–62.
Flatow V, Warner RR, Overbey K, Divino CM. The prognostic significance of lymph node ratio in carcinoid tumors. Pancreas. 2016;45:342–4.
Martin JA, Warner RR, Aronson A, Wisnivesky JP, Kim MK. Lymph node metastasis in the prognosis of gastroenteropancreatic neuroendocrine tumors. Pancreas. 2017;46:1214–8.
Fields AC, McCarty JC, Ma-Pak L, Lu P, Irani K, Goldberg JE, et al. New lymph node staging for rectal neuroendocrine tumors. J Surg Oncol. 2018;119(1):156–62.
Pak LM, Yang T, Wang J. Further classification for node-positive gastric neuroendocrine neoplasms. J Gastrointest Surg. 2018;23(4):720–9.
Winchester DP, Stewart AK, Phillips JL, Ward EE. The National Cancer Database: past, present, and future. Ann Surg Oncol. 2010;17:4–7.
National Cancer Institute. Surveillance, epidemiology and end results program (SEER) facts sheets. Retrieved 17 November 2018 at seer.cancer.gov.
Kim MK, Warner RRP, Ward SC, et al. Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors. Neuroendocrinology. 2015;101:58–65.
National Comprehensive Cancer Network. NCCN Guidelines for patients: colon cancer. Retrieved 1 December 2018 at https://www.nccn.org/patients/guidelines/colon/index.html.
Acknowledgment
Justin C. McCarty receives fellowship funding from the Gillian Reny Stepping Strong Center for Plastic Surgery Trauma Innovation.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Fields, A.C., McCarty, J.C., Lu, P. et al. Colon Neuroendocrine Tumors: A New Lymph Node Staging Classification. Ann Surg Oncol 26, 2028–2036 (2019). https://doi.org/10.1245/s10434-019-07327-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-019-07327-6